Reader’s guide · First edition · September 2026 · Revised October 1, 2026
GHK-Cu
A guide to the copper peptide: a skin-cream ingredient with fifty years of small studies, and an injection with none
GHK-Cu is a three-amino-acid fragment of a blood protein that binds copper and, in the skin, switches on repair. It has been in cosmetic creams since the 1990s, and the studies behind those creams are real, if small and mostly company-run. In the last two years it has become the best-selling beauty peptide in the research-vial market, sold as a 50 mg powder to inject, and the vial is a different product: the same molecule, no human study of injecting it, and an FDA safety concern on record. This guide covers both forms, tells them apart on every page, and gives the arithmetic for the vial because people are using it.
Who this is for
Written for adults who are using, or being offered, GHK-Cu in a serum, in a clinic procedure, or as an injection for skin, hair, or healing. It summarizes the published record and the regulatory position as of the edition date. It is not medical advice.
GHK is glycyl-histidyl-lysine, a tripeptide released when larger proteins in blood and tissue are broken down. It binds copper tightly, and the copper complex, GHK-Cu, is what reaches cells. It was isolated from human plasma in 1973 by Loren Pickart, who has authored most of the literature on it since. Levels in blood fall with age, which is the observation the whole anti-aging story is built on.
- Class
- Copper-binding tripeptide; naturally present in blood, saliva, and urine
- What it does in cells
- In laboratory studies it raises collagen and elastin production, recruits repair cells to wounds, and shifts the activity of hundreds of genes toward repair and away from inflammation. Almost all of that work is in cultured cells and animals.
- Forms in use
- Serums and creams, commonly around 1% and up to 3%; med-spa application after microneedling; research-chemical vials of 50 or 100 mg for injection; the GLOW and KLOW blend vials, where GHK-Cu is most of the powder by weight
- Status
- As a cosmetic ingredient, lawful and unregulated beyond ordinary cosmetic rules. As an injection, an unapproved drug: not on FDA's compounding list, removed from Category 2 in April 2026 when its nomination was withdrawn, with an advisory committee review promised before the end of February 2027.
- Anti-doping
- Not on the WADA Prohibited List
One name, two products
Every claim in a GHK-Cu advertisement comes from creams, cell cultures, or animals. The vial borrows all of it. Nothing in this guide about the topical evidence transfers to the injection, and the guide says so each time the two meet.
The human record is a handful of small cosmetic studies from the late 1990s and 2000s, most run or funded by the company that sold the creams, and two of the most-cited were presented at meetings rather than published in full. They point the same way: measurable improvement in skin thickness, firmness, and fine lines over about twelve weeks. They are not the same as a drug trial, and they were never meant to be.
| Year | Study | Result | Weight |
|---|---|---|---|
| 1998 | Pilot study of creams (copper peptide, vitamin C, melatonin) against tretinoin on normal skin, with biopsies | Copper peptide cream raised procollagen more than vitamin C or tretinoin in the biopsy samples | Small, histology-based, single center |
| 2002 | 71 women with photoaged skin, GHK-Cu face and eye cream for 12 weeks | Increased skin density and thickness, less laxity, fewer fine lines versus placebo | Meeting abstract, company-run; never published in full |
| 2009 | 60 adults, an over-the-counter anti-aging cream containing a copper peptide among other actives, 6 months, double-blind | Clinically significant improvement in wrinkles, with new fibrillin deposited in treated skin | A real randomized trial, but of a mixed product; the copper peptide's share is unknown |
For hair, the study everyone cites (2007) grew hair follicles in a dish with a related copper peptide, AHK-Cu, not GHK-Cu. There is no standalone placebo-controlled trial of topical GHK-Cu for hair loss.
What this supports
A copper peptide serum is a reasonable cosmetic with modest, measurable effects on the texture and firmness of aging skin, on par with other well-studied cosmetic actives and with a better irritation profile than retinoids. That is a fair claim, and it is the only claim the human evidence carries.
Human trials of injected GHK-Cu, for any purpose, at any dose
Published measurements of what an injected dose does to blood copper, skin, or hair in people
FDA safety statement on record: immunogenicity risk from aggregation and peptide impurities, and limited human safety data
The case for injecting is an inference: if GHK-Cu resets repair genes in a dish and firms skin when applied to it, then putting it in the bloodstream should do that everywhere. No one has tested the inference. Injected peptides of this size are cleared within minutes to hours, and whether any reaches the skin at a meaningful concentration is unmeasured.
- The copper question
- GHK-Cu is about 14% copper by weight. A 2 mg injection delivers roughly 0.3 mg of copper, a third of the daily dietary allowance and well under the 10 mg oral upper limit. Copper overload from clinic doses is unlikely on the arithmetic; the honest problem is that no one has measured it, and injection bypasses the gut's control of absorption.
- What users report
- Injection-site pain and redness, flushing, fatigue, and light-headedness on standing. Unverified, unquantified, and from the same forums that report the benefits.
- What FDA said
- When it listed injectable GHK-Cu as unsuitable for compounding, FDA cited possible aggregation of the peptide, peptide-related impurities, the immune reactions those can provoke, and the absence of human safety data. Those concerns apply to research vials with more force, not less.
What would count as evidence
A placebo-controlled trial of injected GHK-Cu measuring skin thickness or hair density by instrument, with blood copper and immune markers tracked, over three months or more. None exists, and as of this edition none is registered.
| Form | Instruction | What is known |
|---|---|---|
| Serum or cream | About 1% GHK-Cu, once or twice daily, ongoing; the studies ran 12 weeks before measuring | The evidence base; modest effects on aging skin |
| Med spa, after microneedling | Topical GHK-Cu applied to needled skin, in a series of sessions | One 2025 study of a needling-delivered combination with minoxidil and dutasteride for hair; the peptide's own share is unknown |
| Injection, clinic protocol | 1 mg daily for two weeks, then 2 mg daily for two weeks, subcutaneous, then a month off | No human study; the ramp and the rest month are custom |
| GLOW and KLOW blends | 500 mcg to 1 mg of blend daily for four to eight weeks | GHK-Cu is 60 to 70% of the powder; the healing peptides ride along at token doses. No study of any blend |
What the next table is, and is not
It expresses the common clinic injection protocol for the 50 mg vial as sold, so the arithmetic can be checked. Nothing in it has been tested in a human trial, injectable GHK-Cu may not lawfully be compounded, and a research-chemical vial's identity, copper content, and sterility are unverified.
- Vial
- 50 mg, as sold; identity and quantity unverified. A 100 mg vial takes twice the water for the same concentration.
- Water added
- 2.5 mL bacteriostatic water, which a standard 3 mL vial holds. Clinics often use 2 mL, which makes the 1 mg dose a 4-unit draw, too small to measure reliably.
- Concentration
- 20 mg/mL (20,000 mcg/mL). One concentration for the whole course.
- Syringe
- 0.3 mL insulin syringe with half-unit marks; the draws are 5 and 10 units, the smallest this series considers measurable
| Days | Daily dose | Draw | Units | Used per cycle |
|---|---|---|---|---|
| 1–15 | 1 mg (about 0.14 mg copper) | 0.05 mL | 5 | 15 mg |
| 16–30 | 2 mg (about 0.27 mg copper) | 0.1 mL | 10 | 30 mg |
| 31–60 | Off | 45 mg per cycle, about one vial |
The month off is a clinic convention justified by copper, not by data. The copper delivered in the whole cycle is about 6 mg, roughly a week of dietary intake.
What each draw looks like · 0.5 mL (50-unit) U-100 insulin syringe
The plunger tip sits on the line for the dose. Units are marks on a U-100 syringe: 100 units is 1 mL. The picture assumes the concentration in the table above; a different amount of water changes every line.
- The serum route has the evidence, the lowest cost, and the fewest unknowns. A 1% serum used daily for three months is what the studies tested.
- GHK-Cu solutions are blue. A vial that reconstitutes clear is either very dilute or not GHK-Cu.
- The blend vials solve a marketing problem, not a biological one: at the vendors' usual dose, GLOW delivers a full copper-peptide course whether or not the buyer wanted one, and TB-500 at a fraction of what its own sellers recommend alone. The GLOW guide does the arithmetic.
The regulatory line runs exactly where the evidence line does. A cosmetic that changes the appearance of skin needs no FDA approval and may make appearance claims. The moment the same molecule is injected, or claimed to treat a condition, it is a drug, and injectable GHK-Cu is an unapproved one that FDA has specifically said pharmacies should not make.
| Form | Legal position | What the buyer gets |
|---|---|---|
| Serum or cream | A cosmetic. Lawful without approval as long as claims stay cosmetic (firmer, smoother) rather than medical (treats, heals) | A product with decades of use and a known irritation profile; quality varies by brand |
| Injected at a med spa | A drug use. No approved product exists and no compounding pathway is open, so the vial comes from a chemical supplier | The topical evidence, cited for a route it does not cover |
| Research-chemical vial | An unapproved new drug, whatever the label says | Unverified peptide, unverified copper, no sterility certification, no beyond-use date |
| Date | Event |
|---|---|
| 1973 | GHK isolated from human plasma; copper binding described over the following decade |
| 1990s–2000s | Copper peptide cosmetics reach the market; the small skin studies are run |
| 2018 | A gene-expression review argues GHK-Cu resets repair genes; it is the source of most current marketing |
| 2024–2025 | FDA places injectable GHK-Cu in Category 2 of the 503A bulks list: not to be compounded, citing immunogenicity and limited safety data |
| Apr 2026 | The injectable nomination is withdrawn and GHK-Cu leaves Category 2. FDA says it will consult its advisory committee before the end of February 2027 |
| Jul 2026 | The advisory committee recommends six other peptides for compounding; GHK-Cu is not on the agenda |
Leaving the list did not open a door
Removal from Category 2 means FDA is no longer actively evaluating the injectable, because its sponsor withdrew. It does not mean the injectable may be compounded. FDA's 2023 safety statement was never retracted; the agency simply moved GHK-Cu from its active safety-risk list to a 'withdrawn' section when the nominator walked away. Until the committee meets and a rule follows, an injected GHK-Cu vial has no lawful maker.
Reading a vial: the milligram arithmetic8
GHK-Cu doses are in milligrams and the vials are large, so the draws are small. That makes it the peptide where too little water is the common error: a 50 mg vial with 1 mL of water puts a 1 mg dose at 2 units, which no one can measure. The blend vials add a second problem, because most of the powder is GHK-Cu and the other peptides are diluted to a fraction of their usual doses.
units = (dose mg ÷ concentration mg/mL) × 100
A 50 mg vial reconstituted with 2.5 mL of bacteriostatic water is 20 mg/mL. A 1 mg dose is 0.05 mL, or 5 units on a U-100 insulin syringe; 2 mg is 10 units.
| Water added | Concentration | 1 mg | 2 mg |
|---|---|---|---|
| 1 mL | 50 mg/mL | 2 units (not measurable) | 4 units |
| 2 mL | 25 mg/mL | 4 units | 8 units |
| 2.5 mL | 20 mg/mL | 5 units | 10 units |
| 3 mL | 16.7 mg/mL | 6 units | 12 units |
In a 70 mg GLOW vial, 1 mg of blend contains about 0.7 mg of GHK-Cu and roughly 0.14 mg each of BPC-157 and TB-500, a quarter to half of what those are sold at alone. Reconstituted GHK-Cu is blue and light-sensitive; keep it refrigerated and assume it degrades within weeks.
Topical GHK-Cu has a long, quiet safety record. Injected GHK-Cu has no record at all, and the reassurance that it is a natural molecule already in the blood does not answer the question, because the blood level is a few hundred nanograms per milliliter and a 2 mg injection is thousands of times that.
- Topical
- Mild irritation or redness in some users; rare allergy; the blue product can stain fabric. No systemic effects measured in the cream studies.
- Injection, reported
- Injection-site pain and redness, flushing, fatigue, light-headedness. Community reports, uncounted.
- Copper
- About 0.3 mg per 2 mg dose, against a dietary allowance of 0.9 mg a day and an oral upper limit of 10 mg. Not a plausible overload at clinic doses, but unmeasured by the injected route; unexplained fatigue, abdominal pain, or neurological symptoms are a reason to stop and test.
- Immune
- FDA's stated concern: aggregated peptide and synthesis impurities can provoke immune reactions. Peptide vials from chemical suppliers carry exactly those impurities.
- Theoretical
- GHK-Cu promotes new blood-vessel growth and cell migration, the same programs tumors use. No study has examined systemic use in anyone with cancer or a cancer history.
- Sterility
- Research-chemical vials are not certified sterile or endotoxin-free for injection.
- Unknown
- Effects in pregnancy, with Wilson's disease or other copper disorders, with other injected peptides, and beyond a few weeks of use.
- Is this a cream or a vial? If a vial, who made it, and can they show a certificate of analysis with identity and copper content?
- What is the human evidence for the injected route? (There is none.) Which study is being cited, and was it a cream?
- What is the concentration after mixing, and is my 1 mg dose at least 5 units on the syringe?
- Do I have a cancer history, a copper disorder, or am I pregnant?
- For a blend: how much of each peptide is actually in my daily dose, and does that match what the seller recommends for it alone?
- What is being measured to decide whether it works, and by when?
- If a serum has the evidence and costs a tenth as much, why am I injecting it?
What does have evidence for aging skin
Daily sunscreen, which has the strongest data of anything in cosmetics; prescription tretinoin, with decades of controlled trials; and, among cosmetic actives, copper peptide and vitamin C serums with the small studies described here. For hair loss: minoxidil and finasteride, both approved, both trialed. The vial is the one option on the shelf with no evidence at all.
Latest
Developments since this edition, newest first. Items here are dated and sourced; they update the guide without re-editing it.
NPR: injected GHK-Cu has no published human studies; a clinician reports raised liver enzymes and copper
NPR reported that the move from copper-peptide creams to injections has no published human safety or efficacy data behind it, and that FDA's advisory committee is due to take up injectable GHK-Cu in February. A Seattle-area nurse practitioner described injection-site infections and patients with raised liver enzymes and copper levels after self-injecting; these are clinic observations, not a published case series.
UCLA review of 565 studies finds almost no human evidence for six popular recovery peptides
Orthopedic researchers reviewed 565 studies of BPC-157, TB-500, CJC-1295, ipamorelin, MK-677, and GHK-Cu for muscle, tendon, and joint use (American Journal of Sports Medicine, 2026). More than two-thirds were animal-only, and the authors found essentially no studies showing a significant clinical benefit for musculoskeletal conditions.
Committee review of GHK-Cu deferred to a meeting before March 2027
After the July votes on seven other peptides, FDA said the committee will take up GHK-Cu, Melanotan II, LL-37, dihexa, and PEG-MGF at a further meeting before the end of February 2027. No date or docket has been published.
GHK-Cu confirmed absent from the July agenda
A law-firm preview lists GHK-Cu among five peptides held for the follow-up session, separate from the July vote on BPC-157, KPV, TB-500, and the others.
Leaving Category 2 does not make injected GHK-Cu compoundable
A regulatory note confirms FDA's own statement that removal from Category 2 in April 2026 followed the nominator's withdrawal and does not by itself establish eligibility for compounding.
References
- 1.Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
- 2.Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
- 3.Abdulghani AA, et al. Effects of topical creams containing vitamin C, a copper-binding peptide cream and melatonin compared with tretinoin on the ultrastructure of normal skin: a pilot clinical, histologic, and ultrastructural study. Dis Manag Clin Outcomes. 1998;1:136-141.
- 4.Leyden J, Stephens T, Finkey M, Appa Y, Barkovic S. Skin care benefits of copper peptide containing facial cream. American Academy of Dermatology 60th Annual Meeting, New Orleans, February 2002 (abstract).
- 5.Watson REB, et al. A cosmetic 'anti-ageing' product improves photoaged skin: a double-blind, randomized controlled trial. Br J Dermatol. 2009;161(2):419-426. https://pubmed.ncbi.nlm.nih.gov/19438432/
- 6.Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327-345. https://onlinelibrary.wiley.com/doi/full/10.1111/j.1468-2494.2009.00490.x
- 7.Pyo HK, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-839.
- 8.The Peptide Catalog. GHK-Cu dosage chart: subcutaneous and topical (2026); and vendor listings for 50 mg and 100 mg vials and the GLOW and KLOW blends, as sold September 2026. https://thepeptidecatalog.com/articles/ghk-cu-dosing-guide
- 9.U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (GHK-Cu, injectable routes). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- 10.U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A (April 2026 update: withdrawn nominations, including GHK-Cu, and planned advisory committee consultation). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act
- 11.National Institutes of Health, Office of Dietary Supplements. Copper: fact sheet for health professionals (recommended dietary allowance 0.9 mg; tolerable upper intake level 10 mg). https://ods.od.nih.gov/factsheets/Copper-HealthProfessional/